Abstract
Traumatic brain injury, often referred to as the “silent epidemic,” is a nondegenerative, non-congenital insult to the brain due to a blow or penetrating object that disrupts the function of the brain leading to permanent or temporary impairment of cognition, physical and psychosocial functions. Traumatic brain injury usually has poor prognosis for long-term treatment and is a major cause of mortality and morbidity worldwide; approximately 10 million deaths and/or hospitalizations annually are directly related to traumatic brain injury. Traumatic brain injury involves primary and secondary insults. Primary injury occurs during the initial insult, and results from direct or indirect force applied to the physical structures of the brain. Secondary injury is characterized by longer-term degeneration of neurons, glial cells, and vascular tissues due to activation of several proteases, glutamate and pro-inflammatory cytokine secretion. In addition, there is growing evidence that the blood-brain barrier is involved in the course of traumatic brain injury pathophysiology and has detrimental effects on the overall pathology of brain trauma, as will be discussed in this work.
Keywords: Biomarkers, blood-brain barrier, brain injury, connexins, cytokines, inflammation, neuronal injury, traumatic brain injury.
CNS & Neurological Disorders - Drug Targets
Title:Traumatic Brain Injury and Blood-Brain Barrier Cross-Talk
Volume: 15 Issue: 9
Author(s): Mohammad Nasser, Fabienne Bejjani, Mohamad Raad, Hadi Abou-El-Hassan, Sarah Mantash, Amaly Nokkari, Naify Ramadan, Nouhad Kassem, Stefania Mondello, Eva Hamade, Hala Darwish, Kazem Zibara and Firas Kobeissy
Affiliation:
Keywords: Biomarkers, blood-brain barrier, brain injury, connexins, cytokines, inflammation, neuronal injury, traumatic brain injury.
Abstract: Traumatic brain injury, often referred to as the “silent epidemic,” is a nondegenerative, non-congenital insult to the brain due to a blow or penetrating object that disrupts the function of the brain leading to permanent or temporary impairment of cognition, physical and psychosocial functions. Traumatic brain injury usually has poor prognosis for long-term treatment and is a major cause of mortality and morbidity worldwide; approximately 10 million deaths and/or hospitalizations annually are directly related to traumatic brain injury. Traumatic brain injury involves primary and secondary insults. Primary injury occurs during the initial insult, and results from direct or indirect force applied to the physical structures of the brain. Secondary injury is characterized by longer-term degeneration of neurons, glial cells, and vascular tissues due to activation of several proteases, glutamate and pro-inflammatory cytokine secretion. In addition, there is growing evidence that the blood-brain barrier is involved in the course of traumatic brain injury pathophysiology and has detrimental effects on the overall pathology of brain trauma, as will be discussed in this work.
Export Options
About this article
Cite this article as:
Nasser Mohammad, Bejjani Fabienne, Raad Mohamad, Abou-El-Hassan Hadi, Mantash Sarah, Nokkari Amaly, Ramadan Naify, Kassem Nouhad, Mondello Stefania, Hamade Eva, Darwish Hala, Zibara Kazem and Kobeissy Firas, Traumatic Brain Injury and Blood-Brain Barrier Cross-Talk, CNS & Neurological Disorders - Drug Targets 2016; 15 (9) . https://dx.doi.org/10.2174/1871527315666160815093525
DOI https://dx.doi.org/10.2174/1871527315666160815093525 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Calcium Metabolism and Oxidative Stress in Bone Fractures: Role of Antioxidants
Current Drug Metabolism Free Fatty Acids: Circulating Contributors of Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Neurodegeneration in the Brain Tumor Microenvironment: Glutamate in the Limelight
Current Neuropharmacology Editorial [Hot Topic: Regulation of Glutamate Synthesis Via Inhibition of Glutamate Carboxypeptidase II (GCPII): An Effective Method to Treat Central and Peripheral Nervous System Disorders (Guest Editors: Guido Cavaletti and Barbara Slusher)]
Current Medicinal Chemistry Stem Cell Therapies for Intracerebral Hemorrhages
Current Drug Delivery MDMA Toxicity and Pathological Consequences: A Review About Experimental Data and Autopsy Findings
Current Pharmaceutical Biotechnology Computer-aided Drug Design Applied to Parkinson Targets
Current Neuropharmacology Anesthetic and Adjunctive Drugs for Fast-Track Surgery
Current Drug Targets Plasminogen Activation-Based Thrombolysis for Ischaemic Stroke: The Diversity of Targets may Demand New Approaches
Current Drug Targets Purines and Pyrimidines: Metabolism, Function and Potential as Therapeutic Options in Neurodegenerative Diseases
Current Protein & Peptide Science The Potential Roles of Metallothionein as a Therapeutic Target for Cerebral Ischemia and Retinal Diseases
Current Pharmaceutical Biotechnology Polymeric Nanoparticles for Ophthalmic Drug Delivery: An Update on Research and Patenting Activity
Recent Patents on Nanomedicine Comparison of the Acute Hematopoietic Capacities of Erythropoietin and U-74389G Concerning Hematocrit Levels
Cardiovascular & Hematological Disorders-Drug Targets Infantile Epileptic Encephalopathy with Hypsarrhythmia (Infantile Spasms/West Syndrome) and Immunity
Central Nervous System Agents in Medicinal Chemistry Molecular Docking and ADME Studies of Natural Compounds of Agarwood Oil for Topical Anti-Inflammatory Activity
Current Computer-Aided Drug Design Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia
CNS & Neurological Disorders - Drug Targets Endothelial Dysfunction: The Link Between Homocysteine and Hydrogen Sulfide
Current Medicinal Chemistry Leptin and Interleukin-1β Modulate Neuronal Glutamate Release and Protect Against Glucose-Oxygen-Serum Deprivation
Current Neurovascular Research Recombinant Tissue-Type Plasminogen Activator (Alteplase) in the Management of Acute Ischemic Stroke: A Review of its Pharmacological Properties, Efficacy, Safety and Pharmacoeconomic Aspects
Current Drug Therapy Targeting Matrix Metalloproteinases in Inflammatory Conditions
Current Drug Targets